COVID-19: Could Aspirin Be of Any Help in the Early Stage?

7 Pages Posted: 21 Apr 2020 Last revised: 16 Jun 2020

See all articles by Giovanni Francesco Delogu

Giovanni Francesco Delogu

Department of Neurology, Ospedale di Livorno (Italy)

Date Written: April 14, 2020


Here is discussed the current scientific background for starting antiaggregation with Aspirin in the very initial phase of COVID-19 infection for preventing thrombotic infarctions before irreversible damage occurs in the target organs.

Several authors are now describing the presence of endothelial cells into the bloodstream. This might indeed represent an epiphenomenon of the underlying mechanisms explaining the incidence of fatal systemic thrombotic complications.

Antiaggregation with ASA would potentially have a significant prophylactic role, ideally before than anticoagulation and/or intensive care be the only options left: therefore dedicated trials should urgently be addressed to confirm this hypothesis.

Note: Funding: None to declare

Declaration of Interest: None to declare

Keywords: COVID-19, Aspirin, antiaggregation, thrombosis, viral sepsis, endothelial cells

Suggested Citation

Delogu, Giovanni Francesco, COVID-19: Could Aspirin Be of Any Help in the Early Stage? (April 14, 2020). Available at SSRN: or

Giovanni Francesco Delogu (Contact Author)

Department of Neurology, Ospedale di Livorno (Italy) ( email )

Viale Vittorio Alfieri 36
+39-0586223317 (Phone)

Do you have negative results from your research you’d like to share?

Paper statistics

Abstract Views
PlumX Metrics